(Q36910188)

17 August 2017

1 reference

title

Anti-immunoglobulin E therapy with omalizumab for asthma (English)

1 reference

17 August 2017

1 reference

Leslie Hendeles

1

1 reference

17 August 2017

Christine A Sorkness

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

14 August 2007

1 reference

Annals of Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

41

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

1397-1410

1 reference

Unmet needs in adult asthma

17 August 2017

cites work

1 reference

Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma

21 January 2018

1 reference

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

21 January 2018

1 reference

Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells

21 January 2018

1 reference

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

21 January 2018

1 reference

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

21 January 2018

1 reference

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

21 January 2018

1 reference

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma

21 January 2018

1 reference

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.

21 January 2018

1 reference

Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma

21 January 2018

1 reference

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

21 January 2018

1 reference

Omalizumab is effective in the long-term control of severe allergic asthma

21 January 2018

1 reference

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

21 January 2018

1 reference

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

21 January 2018

1 reference

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.

21 January 2018

1 reference

Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma

21 January 2018

1 reference

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

21 January 2018

1 reference

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

Omalizumab improves asthma-related quality of life in children with allergic asthma

21 January 2018

1 reference

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

21 January 2018

1 reference

Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody

21 January 2018

1 reference

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

21 January 2018

1 reference

Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma

21 January 2018

1 reference

Self-reported adherence in patients with asthma

21 January 2018

1 reference

Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma

21 January 2018

1 reference

Should patients with persistent severe asthma be monitored for medication adherence?

21 January 2018

1 reference

Directly observed therapy and treatment adherence

21 January 2018

1 reference

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma

21 January 2018

1 reference

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1K005

1 reference

17 August 2017

1 reference